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ABSTRACT 
Objective: Binge eating disorders (BED) recently become a global health care issue for clinicians with detrimental effects on all organ systems. A 
multidisciplinary strategy including pharmacotherapy is required for its management. 
Methods: This review is intended to comparatively evaluate the relative efficacy of different pharmacological agents in BED treatment with new 
therapeutic approaches, focusing on the clinical evidence and on Phase III randomized controlled trials. 
Results: Data suggest that certain treatments have advantages over placebos to reduce binge eating features; however, the small duration of such 
research with the lack of adequately sized trials was the major limitation in interpreting these findings. Furthermore, these medications are mostly 
not greatly efficient for BED associated with obesity except for topiramate, which markedly improves the features of binge episodes with weight 
loss. Till now, lisdexamfetamine is still the only drug with regulatory permission for BED therapy; however, its weight loss efficacy has not been 
established. 
Conclusion: Drugs alone or in combination approaches may be useful pharmacotherapies to yield promising outcomes acutely and over longer-
term follow-up in the treatment of BED. 
Keywords: Binge eating disorder, Obesity, Binge-episodes, Pharmacotherapy, Lisdexamfetamine 
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/) 
DOI: https://dx.doi.org/10.22159/ijap.2021v13i2.40214. Journal homepage: https://innovareacademics.in/journals/index.php/ijap  
 
INTRODUCTION 
The Diagnostic and Statistical Manual of Mental Disorders, fifth 
edition, (DSM-V) considered binge eating disorder (BED) as a 
distinct diagnosis of eating disorder [1]. BED is described by 
repeated binge-eating episodes, consuming within a short time 
(<2 h) unusually large quantities of food. The individual experiences 
marked distress and excessive control loss of binge eating without 
compensatory behaviors of weight loss (such as abuse of diuretics or 
laxatives, inducing vomiting, intense exercise) characterizing 
bulimia nervosa [2]. Studies propose that episodes of binge eating in 
BED may be lower than in bulimia nervosa [3]. The marked distress 
needed for the determination involves a disagreeable emotional 
state through the binge episodes, along with fears regarding the 
continuing effects on body weight and shape. The length of an 
episode can differ significantly, and many individuals have difficulty 
separating binge eating into discrete episodes. However, they 
generally display some challenges in remembering if binge eating 
occurs on a specified day or not. It is therefore recommended that 
the frequency of binge days, not just binge episodes, should be 
assessed, as in bulimia nervosa diagnosis [4]. 
The DSM-IV stated that the average incidence of binge eating episodes 
over the previous 6 mo was at least 2 d a week; in DSM-V, this was 
changed to at least once a week for ≥ 3 mo. Regarding the DSM-V 
standards, determination of BED is stated if frequent episodes of binge 
eating involve not less than three features: eat more quickly than 
usual, eat until uncomfortably complete, eat much food without feeling 
hungry, eat alone because of emotions of embarrassment, feel 
disgusted, embarrassed, or depressed as a result of overeating. Also, 
the DSM-V defined the least severity grade relative to the frequency of 
weekly binge episodes (mild, 1–3; moderate, 4–7; severe, 8–13; and 
extreme, ≥14 wly episodes) so that severity degree may also be useful 
for reflecting the impairment of other functions [5, 6]. 
BED is one of the prominent eating disorders in the United States 
and worldwide [7] that has the highest incidence in adolescence [8]. 
Also, BED is more prevalent in women, related to concerns about 
thinness and shape [9]. Clinical trials indicate that altering 
concentrations of both estrogen and progesterone are probable to 
add the risk of BED and probably its prevalence in women [10], in 
addition to, stress as a potential ovarian hormone moderator that 
affects binge eating in females [11, 12]. 
Overall, the episodes of BED are related to increased eating disorder 
(eg, weight gain and shape concern) and general psychopathology 
(eg, depressiveness, anxiety), and highly comorbid with mood 
disorders (49%), anxiety disorders (41%), and substance abuse 
disorders (22%) that definitely affects the quality of life and health 
of an individual [13]. In addition, The BED recurrently cooccurs with 
attention-deficit/hyperactivity disorder [14] and is accompanied by 
chronic illnesses such as diabetes, hypertension, and 
hyperlipidemia; therefore, BED displays similar psychological 
impairments as the other well-defined eating disorders [15]. BED 
appears to be more common as the obesity grade rises and is linked 
with risk factors that increase the chance of weight gain (with body 
mass index, BMI ≥30.0 kg/m 2
Survey methodology 
). Obese individuals with BED have a 
fear of negative evaluation, less self-confidence and more prone to 
depression than obese patients without BED [16]. BED patients are 
more vulnerable to the report of dietary disinhibition, unnecessary 
shape and weight concerns, and difficulty in interpreting hunger and 
satiety-related visceral sensations. In addition, they are more 
probable to become overweight at a younger age than obese people 
without BED, begin diet at a younger age and spend more time on 
unsuccessful efforts to weight loss. Overweight people with BED feel 
more overweight and fatter than others with similar weight [17]. 
Three electronic databases (PubMed, Science Direct, and Google 
Scholar) have been systematically searched for published English-
language articles in all periods up to September 2019. We used 
terms related to “binge episodes”, “binge eating disorder”, “bulimia 
nervosa”, “obesity”, “pharmacotherapy”, “antidepressants”, 
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“anticonvulsants”, “antiobesity”, “anorectic”, “antiaddiction drugs”, 
“opioid antagonists”, “Attention deficit hyperactivity disorder 
(ADHD)” and individual medications (eg. “lisdexamfetamine (LDX)”, 
“atomoxetine”, “topiramate”, “lamotrigine”, “methylphenidate”, 
“acamprosate”, “naltrexone”, “d-fenfluramine”, “liraglutide”, 
“chromium”, “baclofen”, and “vortioxetine”). Relevant articles were 
then screened for references of this review. 
Pharmacological treatment 
The first therapeutic approaches for BED were obtained from 
bulimia nervosa or various research on the therapy of obesity and 
depression. When various studies revealed significant variations in 
psychopathology, consideration of a definite treatment strategy has 
become clear [18]. The treatment of BED is multidimensional, so a 
number of pharmacological and psychological strategies have been 
designed and evaluated in diverse studies [19]. This paper provides 
the rationale of the main pharmacological treatments administered 
alone or in combinations for patients with BED and reviews their 
effectiveness according to the previous clinical findings with 
patients had BED. 
The use of pharmacotherapy to treat BED has several reasons. Like 
other psychiatric condition, as depression, anxiety, and personality 
disorders, as well as substance abuse, BED is a mental case with 
hereditary and neurobiological disorder causing distress, and 
dysfunction and does not always react sufficiently to current 
psychological therapy [20]. The more we learn about eating 
behavior, and diagnosis of eating disorder, neuroimaging work 
widely explains the neurobiology of binge eating [21]. Animal binge 
eating models show the impact of dopamine, norepinephrine, and 
opioid systems, all influencing eating behavior [22]. A behavioral 
study has proposed a critical function for the serotonin system, as 
mice that lack 5HT2C
This review article currently summarizes and compares the different 
drug classes used for the treatment of BED based on their 
pharmacological rationales. 
 functional receptors show noticeable 
hyperphagia, leading to obesity progression [23]. Also, animal 
findings display that BED is concomitant with changes in the 
gastrointestinal tract. For example, repeated gastric distensions alter 
the intake of food and neuroendocrine profiles in rats [24]. 
Additionally, many treatments available affects variable 
neurotransmitter systems implicated in appetite or weight 
management, which can have beneficial effects on BED treatment.  
Antidepressants  
Antidepressants were among the first medications assessed for BED 
treatment. BED mostly come with other depressive and anxiety 
disorders. It remains questionable whether the improvements 
achieved with antidepressants are associated principally with 
improvement in BED outcomes or concomitant mood or anxiety 
features. Also, BED may be linked to abnormalities in 
neurotransmitter systems including serotonin, norepinephrine and 
dopamine which most antidepressants target [20]. 
Selective serotonin reuptake inhibitors (SSRIs)  
There has been an inverse relationship between serotonin levels and 
food consumption, where a selective serotonin decrease is related to 
hyperphagia and consequent weight gain; alternatively, lowering the 
consumption of food generally leads to increased serotonin circulation. 
The most commonly used SSRIs are fluoxetine, fluvoxamine, sertraline, 
citalopram, and escitalopram. Several clinical studies assessed their 
efficacy in BED therapy regarding decreases in weight, the frequency 
of binge episodes, and binge days [25]. 
Fluoxetine is the only official drug allowed for bulimia nervosa 
therapy by the Food and Drug Administration (FDA) and can reduce 
food intake and body weight [26]. In 1996, the first randomized 
controlled double-blind study was designed to assess fluoxetine 
efficacy for 6 d [27]. A sample of 79 overweight women (38 of them 
had BED) with a BMI (30-45 kg/m2
An open-pilot 9-week study involving 5 BED patients proposed the 
effectiveness of fluvoxamine in BED therapy [31]. The 
administration of fluvoxamine at a daily dose (100 to 200 mg) was 
related to decrease in binge eating frequency, weight loss, and 
anxiety level. A randomized, controlled, double-blind trial involving 
85 obese patients with BED established later these findings of 
fluvoxamine at a daily dose (50–300 mg for 9 w) [32]. But there was 
a practical limitation in both studies such as insignificant sample size 
and short trial period. In addition, a randomized, controlled, double-
blind study lasting 12 w doubts the promising outcomes of the 
previous research [33]. The study showed that fluvoxamine (150 
mg/day) had the same efficacy of placebo in the binge eating 
frequency, weight changes, and improvement in depressive 
symptoms.  
) received flexible doses of 
fluoxetine (up to 60 mg/d). This was accompanied by a significant 
reduction in caloric consumption of around 600 kcal/d (p<0.007), 
while the of binge eating frequency did not reduce significantly 
(P<0.45). A 6-week, randomized, controlled trial conducted on 60 
obese patients with BED showed similar findings [28]. The study 
showed that fluoxetine daily doses of 20 to 80 mg were well 
tolerated and significantly reduce the binge-eating frequency, body 
weight, BMI, and severity of disease along with relieving depressive 
symptoms. However, another randomized 16-week double-blind 
study that compared the efficacy of fluoxetine and cognitive-
behavioral therapy (CBT) did not confirm the findings of these two 
studies [29]. Fluoxetine (60 mg/day), CBT plus fluoxetine, CBT plus 
placebo, or placebo were randomly assigned to 108 patients with 
BED. CBT exhibited efficacy for binge eating remission rates, 
cognitive and psychological symptoms when added to fluoxetine or 
placebo. Additionally, the combination of fluoxetine plus CBT 
showed no superiority over CBT alone. These findings were also 
established by another study conducted on 116 patients with BED 
who received behavioral weight control therapy [30]. Patients 
randomly received adjunctive CBT or no CBT and to fluoxetine or 
placebo for 20 w. However, fluoxetine (40–80 mg/d) showed 
efficiency in decreasing depressive features. 
A 6-week, randomized, controlled, double-blind study assessed 
sertraline (50–200 mg/day) on 34 obese participants with BED [34]. 
Sertraline had advantages over placebo for reducing binge episodes 
frequency, the severity of disease (p<0.001) and BMI (p =0.002). 
These results were in line with a 12-week, randomized, parallel-
group, controlled study, in which a sample of 20 bulimic patients 
received daily sertraline (100 mg) [35]. There was a significant 
reduction in the binge episodes frequency and weight change after 2 
w. A third study was conducted on 32 obese patients (14 diagnosed 
with BED and 18 with a Binge Eating Scale (BES) high score, but not 
meeting the BED criteria) who received sertraline treatment (100 to 
200 mg/day for 24 w) [36]. After a 5-week follow-up, sertraline 
significantly decreased body weight and the frequency of weekly 
binge episodes with a significant improvement (p<0.002) in BES 
score. A randomized, double-blind, controlled study evaluating 
sertraline and fluoxetine in forty-two females with BED and obesity 
was performed. Twenty-two females were treated daily with 
sertraline (100–200 mg) and the other twenty with fluoxetine (40–
80 mg) for 6-month treatment [37]. The study showed the positive 
impacts of continuous SSRI treatment on patients who initially 
responded to SSRIs for up to 6 mo with reduced binge eating 
episodes and weight loss. 
The first randomized, controlled study evaluating the tolerability 
and effectiveness of citalopram in BED treatment involved 38 
patients who received daily for 6 w citalopram dose (20 to 60 mg) or 
a placebo [38]. The study showed significant superiority of 
citalopram for decreasing weekly binge eating frequency, BMI, and 
body weight.  
A 12-week, randomized placebo-controlled trial evaluated the 
efficacy of escitalopram in 44 obese participants with BED [39]. 
Escitalopram (up to 30 mg/day) was useful for weight loss, with a 
significant BMI reduction (p=0.048), and global severity of illness 
scores (p=0.026) but was not efficacious in reducing the binge 
episodes frequency, weekly binge days, and obsessive-compulsive 
symptoms. 
Vortioxetine is a novel atypical antidepressant that received the FDA 
approval for the major depressive disorder treatment in 2013. 
Vortioxetine enhance serotonin levels via a dual mechanism of 
action as serotonin reuptake inhibitors and serotonin modulators. 
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Vortioxetine also increases in certain areas the levels of 
noradrenaline, dopamine, and acetylcholine, along with modulating 
neurotransmission of γ-aminobutyric acid and glutamate [40, 41]. 
Furthermore, vortioxetine seems to have the potential for cognitive 
enhancement, which may have benefits in disorders characterized 
by executive dyscontrol. This proposes that drug could alleviate the 
BED symptoms by complementary pathways [42]. The efficacy of 
vortioxetine in BED treatment was evaluated by a 12-week, double-
blind, controlled study. Eighty adult patients with BED randomly 
assigned in a parallel design to vortioxetine (10 mg/day for the first 
week, then up to 20 mg/day) and placebo. Vortioxetine was not 
superior to placebo in reducing the binge-eating frequency, weight, 
and BMI with a good tolerability profile. So, further trials needed to 
evaluate its efficacy in BED treatment [43]. 
Serotonin and norepinephrine reuptake inhibitors (SNRIs) 
The drugs including duloxetine, and venlafaxine appeared to have a 
synergetic effect in BED therapy by having dual actions inhibiting 
reuptake of both 5-HT and NE [44].  
Two case reports indicated that duloxetine was significant in the 
refractory BED therapy, which suggested that nausea and reduced 
appetite would be helpful in the treatment [45, 46]. A 12-week open 
study showed the efficacy of duloxetine at a flexible daily dose (60-
120 mg) in 45 obese patients with BED or subthreshold BED 
symptoms [47]. Duloxetine significantly reduced weight, BMI and 
disease severity, as well as improved depressive symptoms. Similar 
results were observed in a randomized, 12-week, double-blind, 
controlled study involving 40 depressed participants with BED [48]. 
Duloxetine (30–120 mg/day) significantly reduced the frequency of 
binge episodes, binge days, and body weight, besides a significant 
relief (p = 0.01) in depressive disorder score.  
On the other hand, there was only one retrospective trial conducted 
on 35 overweight or obese patients with BED [49]. The superior 
effect of venlafaxine (75-300 mg/day for 120 d) to placebo was 
recorded in decreasing weight, BMI (p =0.02), and severity of illness, 
without significant reduction in binge episodes (p =0.08). 
Norepinephrine reuptake inhibitors 
In 12-week open trial, the effectiveness and safety of reboxetine at a 
daily dose (8 mg) were evaluated on 9 obese subjects with BED [50]. 
Five patients experienced significant improvements in the frequency 
of binge eating and general quality of life. There was also a 
statistically significant reduction in Mean BES scores (p =0.0003) 
and BMI (p =0.01) with no serious adverse events. 
Norepinephrine-dopamine reuptake inhibitors 
Multiple studies revealed that bupropion able to improve 
hyperphagic depressed individuals and overweight or obese 
patients with depression [51-55]. The efficacy of bupropion and 
sertraline in the treatment of BED and comorbid depression was 
comparably evaluated in a 24-week retrospective cohort study [56]. 
The study involved 15 patients who received bupropion (150 mg per 
day) and the other 15 received sertraline (200 mg per day). During 
the first 6 w of treatment, bupropion and sertraline had similar 
efficacy in improving weight loss, however, after completion of the 
study period, bupropion showed a superior improvement in 
promoting weight loss (5.5±3.6 kg) and was proportional to BMI 
which was not the case with the sertraline group who had 1.9±1.2 kg 
weight reduction. On the other hand, bupropion and sertraline had 
similar advantages in improving depression features and reducing 
the frequency of binge eating with the same tolerability profile. At 
week 24, patients who received bupropion showed a 75% reduction 
of weekly binges compared to 72% in the sertraline group. A 
complete binges remission was also recorded for 53% of the 
bupropion group at week 24 versus 33% for the sertraline group.  
Another randomized, 8-week, double-blind, controlled study 
involved 61 depressed, obese females with BED who received 
bupropion (300 mg/day) [57]. The short-term results showed 
bupropion with a significant BMI reduction (p =0.002) but the 
frequency of binge episodes, food cravings, and depressive features 
was not improved significantly. These results may refer to the lower 
bupropion dosing for short period comparing to the previous 
studies. Currently, combinations of bupropion with other 
treatments are investigated for the therapy of BED and comorbid 
obesity [58, 59]. 
Tricyclic antidepressants (TCAs) 
Tricyclic antidepressants were conflicting about reducing binge 
episodes frequency and body weight [20]. Among TCAs, the efficacy 
of imipramine at a low dose (75 mg/day) was assessed in an 8-week, 
randomized, double-blind, controlled study, following a 6-
month open extension phase [60]. The trial was conducted on a 
sample of 31 obese binge eaters. It was significantly effective to add 
imipramine to dietary counseling with psychological support in 
reducing binge episodes, and body weight along with improving 
depressed mood (p =0.02) as assessed by the Hamilton Scale for 
Depression. Of interest, the beneficial effect was maintained by 
patients receiving imipramine for 26 w after treatment. 
Anticonvulsants (GABAergic and glutamatergic modulators) 
Anticonvulsant drugs appeared to have a beneficial impact on the 
treatment of bipolar disorder and impulse-control disorders, which 
is associated with their potential effect in BED therapy [61]. 
Anticonvulsants, administered alone or in combination therapy, 
showed efficacy in the treatment of BED and obesity for their 
significant anorectic effect [62]. Anticonvulsants affect the system of 
neurotransmitters or peptides that regulate eating behavior. 
However, Drugs such as Phenytoin, valproate, and carbamazepine 
may be promptly abandoned due to their ability to increase appetite 
and weight which may counteract their beneficial effect [63]. 
Topiramate is a sulfamate-substituted monosaccharide which is 
officially permitted in epilepsy therapy and prophylaxis of migraine. 
Topiramate, due to inhibition of the excitatory glutamate pathway in 
the lateral hypothalamus, might have a specific effect on appetite 
suppression and recovery of overeating control. Topiramate use in 
BED patients significantly reduces the frequency of binge episodes 
and body weight but cognitive impairment makes it hard to tolerate 
[64]. A 14-week, randomized, double-blind, placebo-controlled study 
on 61 obese subjects with BED assessed the efficacy of topiramate 
(25-600 mg/day) [65]. Topiramate was significantly effective in 
reducing the frequency of binge episodes, weekly binge days, body 
weight (mean −5.9 kg), and BMI (p =0.003). Also, Topiramate 
showed a significant improvement in the severity of disease (p 
=0.02) and the score of Yale-Brown Obsessive-Compulsive Scale 
(p=0.004) as a measure of the compulsive eating behaviors. 
However, topiramate was not significantly (p =0.28) effective in 
improving depressive features as assessed by HRSD. The same 
research group evaluate the long-term efficacy and tolerability of 
topiramate in the 42-week open extension phase of the previous 
trial including the completers (n=35) [66]. The findings revealed 
that there was an enduring improvement in the treatment of BED 
with obesity over the long term but was also related to a high 
discontinuation rate. Similar results were established over a longer 
period in a 16-week RCT involving a larger sample of 394 obese 
patients with BED [67]. Topiramate showed a significant (all p 
values<0.001) decrease in the frequency of binge episodes, weekly 
binge days, body weight, BMI and severity of illness.  
A 21-week, double-blind, randomized, placebo-controlled study of 
73 obese participants with BED evaluated the efficacy of topiramate 
in conjunction with CBT [68]. Patients received 19 CBT sessions 
combined with 206±36 mg/day of topiramate (n =37) or placebo (n 
=3619). Both treatments significantly reduced the frequency of 
binge episodes. However, addition topiramate to CBT topiramate 
had advantages over placebo for significantly reducing body weight 
(P<0.001). The study showed the treatments did not differ 
significantly in reducing the frequency of binge episodes, BES and 
Beck Depression Inventory scores. The authors concluded that 
topiramate in conjugation with CBT enhanced the efficacy of the 
latter for BED therapy, improving short-term binge remission and 
weight loss. To end, Topiramate was also hypothesized to be 
effective in people who had undergone gastric banding surgery. It 
showed the ability for further weight loss in bariatric surgery 
patients [69, 70].  
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Zonisamide is a second-generation anticonvulsant medication with a 
diverse mechanism of actions, including blockade of voltage-gated 
sodium and T-type calcium channels, reduced glutamatergic 
transmission by blocking the potassium-evoked glutamate release, 
and being carbonic anhydrase inhibitor. Interestingly, weight loss 
was stated as a comparatively prevalent side effect in people who 
contributed to zonisamide clinical trials as an anticonvulsant. In an 
open-label prospective trial, flexible daily dose of zonisamide dose 
(100 to 600 mg) significantly reduced binge eating frequency and 
body weight when administered to 15 BED patients [71]. In a larger 
randomized 16-week, placebo-controlled, double-blind trial (n =60), 
the effectiveness of the same dose of zonisamide was again 
investigated [72]. Zonisamide capable of significantly decreasing the 
binge eating frequency, body weight, and severity of disease 
(p<0.001). However, the medication showed poor tolerability due to 
upset adverse events (eg. ataxia, fatigue, difficulty with memory, 
anorexia). Also, zonisamide can be combined with CBT in BED 
patients for reducing weight and binge eating frequency, with 
maintaining results 1 y after the treatment ends [73].  
Finally, it was suggested that lamotrigine decrease binge eating by 
inhibiting the release of presynaptic glutamate as glutamatergic 
stimulation of the lateral hypothalamus results in higher food 
consumption. The efficacy of lamotrigine in BED therapy was 
assessed in a randomized, double-blind, placebo-controlled trial on 
51 obese. Lamotrigine daily dose (236 mg) for 16 w significantly 
reduced the fasting levels of glucose, insulin, and triglycerides and a 
greater weight loss than placebo. However, the frequency of weekly 
binge episodes and binge days was comparable [74]. 
Anti-obesity medications 
BED is concomitant with high comorbidity of overweight and 
obesity. Also, Anti-obesity drugs can have anti-binge eating 
functions, either directly by suppressing appetite or indirectly by 
metabolic effects to increase the satiety threshold. Clinical trials 
were conducted to evaluate the efficiency of such treatments to 
promote weight loss with improving BED-typical symptoms. 
Sibutramine is an inhibitor for noradrenaline and serotonin 
reuptake and, to a lower extent, dopamine and is authorized for 
obesity therapy by the FDA [75]. Sibutramine could promote and 
maintain weight loss by stimulating satiety and the thermogenesis in 
obese patients with BED. Besides, its efficacy in enhancing 
psychopathology related to eating (reduction in weekly binge days) 
and self-reported depression scores in BED patients. However, this 
drug has limited use because of the high risk of serious 
cardiovascular and cerebrovascular problems found in overweight 
or obese patients with pre-existing cardiovascular dysfunction [76]. 
Three randomized double-blind case-control studies have done to 
evaluate sibutramine efficacy in BED treatment. The first study was 
conducted in sixty obese patients with BED received 15 mg daily 
dose of sibutramine or a placebo for 12-week [77]. Another 12-week 
study included 20 obese females with BED who received 
sibutramine at a daily dose of 10 mg [78]. The third study involved 
largest sample size (n =304) who received sibutramine (15 mg/day) 
for a longer period (24-week) [79]. Sibutramine in all these studies 
significantly decreased the frequency of binge episodes, binge days, 
and BMI accompanied with improving depressive features. 
Orlistat is officially allowed by the FDA as an anti-obesity drug as a 
potent pancreatic and gastric lipases inhibitor that works locally in 
the gut lumen with minimal absorption [80]. The research showed 
that orlistat is effective in binge eating control in obese people, 
despite lacking the central nervous system activity. In terms of 
eating disorder psychopathology and psychological distress, there 
have been considerable and similar improvements in orlistat and 
placebo recipients [81]. A 24-week, randomized, double-blind, 
controlled study reinforced the ability of orlistat monotherapy for 
promoting weight loss and metabolic parameters. Eighty-nine obese 
patients with BED received 120 mg orlistat three times per day in 
combination with a hypocaloric diet [82]. Another two randomized, 
placebo-controlled trials assessed the efficacy of orlistat (120 mg 
three times daily) administered with CBT [83] or behavioral weight 
loss (BWL) [84] in the obese patients with BED. In the first trial, 
significant intent-to-treat remission rates for binge episodes were 
associated with adding orlistat to CBT for 12 w, but not at the 3 mo 
of follow-up [83]. However, a significant weight loss was detected 
with adding orlistat to CBT both after therapy and after 3-month 
follow-up. The addition of orlistat or placebo to CBT had the same 
efficacy in increasing psychopathological eating disorders induced 
by BED after treatment and 3-month follow-up. The second trial was 
performed on 79 obese patients with or without BED. Addition of 
orlistat to BWL was not significantly better than the addition of 
placebo in the BED group to improve BMI, binge eating or depressive 
symptoms. However, the addition of orlistat to BWL resulted in 
more weight loss than the addition of placebo in obese patients 
without BED but not with BED patients [84].  
Phentermine is the most widely prescribed anti-obesity medication 
allowed for short-term treatment. Phentermine is a 
sympathomimetic amine that may reduce appetite by stimulating 
norepinephrine release. Phentermine is currently evaluated in 
combinations with topiramate in BED therapy for its efficacy in 
weight loss [85, 62]. A double-blind, randomized study considering 
the effectiveness and safety of extended-release of 
phentermine/topiramate (3.75/23 mg-15/92 mg) in BED was 
investigated on 15 participants for 12 w [86]. Additionally, a 
prospective open trial assessed the efficacy of phentermine-
topiramate extended-release (6.8 to 41.4 mg/day) for 12 w including 
ten obese or overweighed individuals with BED [87]. The 
combination treatment significantly reduced weight, BMI, binge 
eating frequency, clinical severity scores and obsessive-compulsive 
outcomes. However, no long-term studies are available, and it is not 
known if the weight loss persists and how many individuals relapse 
back into obesity.  
Moreover, D-Fenfluramine was appeared to be effective in BED 
treatment due to its serotoninergic action that mediates satiety and 
causes both food consumption and body weight to decrease as well 
as, a powerful serotonin reuptake inhibitor and serotonin releaser of 
its metabolite d-norfenfluramine [88]. An 8-week, randomized, 
double-blind, controlled trial evaluated the potency of d-
fenfluramine up to 30 mg/day in 28 obese females with BED [89]. 
There was a significant decrease in the frequency of binge episodes; 
however, Binge episodes returned to the level of pretreatment 4 mo 
after therapy ended. Studies were stopped and d-fenfluramine was 
no longer available on the world market due to concerns about 
cardiac valve defects and lung hypertension [90]. 
Liraglutide is a glucagon-like analog peptide used in diabetes type 2. 
Liraglutide is appeared to be capable of significantly reducing weight 
[91] and maintaining weight [92]. Forty-four obese patients with 
BED received diet and exercise counseling then were randomized 
with liraglutide (1.8 mg) or placebo in a 12-week double-blind 
controlled pilot trial [93]. Liraglutide treatment significantly 
improved binge eating symptoms evaluated via BES score and 
weight loss. This was accompanied by significant reductions in BMI 
(p<0.001), waist circumference (p<0.004), systolic blood pressure 
(p<0.042), fasting glucose (p =0.027), and total cholesterol (p 
=0.044). It is noteworthy that 81% of liraglutide patients have 
shifted from binge eating to non-binge eating. Recently, a case report 
revealed the effectiveness of liraglutide in a male with compulsive 
food-related behavior associated with autism. The male patient was 
initiated with a daily dose of 0.6 mg and steadily up to 2.4 mg over 
the following 8 w. Treatment with liraglutide revealed immediate 
positive response in the patient’s manifesting by preventing food-
related repetitive thoughts and compulsive eating. There was also a 
significant reduction in the patient's weight after the first week of 
therapy [94]. 
Attention deficit hyperactivity disorder (ADHD) medications  
Most medications used in ADHD treatment modulates dopaminergic 
and norepinephrine circuits, which are linked to the control of 
feeding behavior and reward system along with the binge eating 
biology. These medications demonstrated an anorectic and weight 
loss effect, and preliminary findings indicate that drugs used in 
ADHD like methylamphetamine and methylphenidate mitigate binge 
eating features in bulimic individuals [95]. A relationship between 
BED and ADHD in both adolescents [96] and adults [97] 
has been shown in available data. Interestingly, the incidence of 
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eating disorders in individuals with ADHD is about 12%, while the 
incidence of ADHD in individuals with eating disorders is estimated 
at 5% to 17% [98]. 
Atomoxetine is a selective reuptake inhibitor of norepinephrine that 
showed efficacy in weight loss and reduction of binge episode 
frequency. In a 10-week, randomized, double-blind, controlled study, 
atomoxetine (40 to 120 mg/day, n=40) showed efficacy in reducing 
features of binge eating episodes and weight loss [99]. Still, these 
results should be long-established through larger studies. 
Atomoxetine administration was accompanied by adverse events 
such as loss of appetite, upset stomach, insomnia, headache, 
constipation, and dry mouth [67]. 
While lisdexamfetamine (LDX) is a d-amphetamine prodrug that 
blocks the reuptake of dopamine and norepinephrine and enhances 
their release in the synapse [100]. LDX has been approved in 2015 
for moderate and severe BED treatment [101]. However, LDX 
administration was accompanied by a limitation of use for weight 
reduction. It is attributed to significant depressive symptoms and 
severe cardiovascular problems associated with other 
sympathomimetic medications for weight loss. Several studies 
established the efficacy of LDX in BED treatment [102-106]. A 
randomized, double-blind, forced-dose titration controlled study of 
on 267 participants with BED evaluated the efficacy of LDX. Patients 
received LDX at daily doses of 30, 50, or 70 mg or placebo. Over 3 w, 
LDX dosages were titrated 20 mg/week and remained unchanged 
for the next 8 w. The results presented the optimal dosage of oral 
LDX in reducing binge episodes and binge days at both 50 and 70 
mg/day, but not at 30 mg/day [102]. The same researchers 
evaluated the effectiveness and safety of LDX in two 12-week 
randomized, double-blind, controlled trials. A sample of 383 patients 
participated in the first trial, while 390 patients were engaged in the 
second. Patients received placebo or LDX (50 or 70 mg/day) in the 
first 4 w, followed by 8-week maintenance [103]. LDX was 
significantly superior at 1 w and at 12 w in improving weekly binge 
features, weight loss and binge eating-related secondary measures. 
Another randomized, double-blind, controlled study of 275 
participants who received LDX (50 or 70 mg/day for 6 mo) 
supported the previous findings [104]. An open-label extension 
phase of 604 BED adults assessed the long-term tolerability and 
safety of LDX for 12 mo [105]. A total of 506 participants reported 
adverse events: 7% and 2.8% experienced serious side effects, 
respectively as well as 9% of the participants required to stop 
therapy while 369 participants completed the study. Dry mouth, 
vision changes, poor appetite and stomach pain were the most 
prevalent side effects identified in more than 10 percent of patients. 
Also, two randomized, double-blind, controlled trials evaluated the 
12-week endpoints related to LDX efficacy. Efficacy measures were 
improved at 1 w, which was maintained in adults with BED 
throughout the 12-week research [106].  
Methylphenidate, a psychomotor stimulant, is a first-line ADHD 
medication. It acts by binding to the dopamine transporter inhibiting 
the dopamine reuptake with enhancing synaptic dopamine. A 
double-blind, controlled crossover trial of 32 participants with BED 
and 46 healthy age-matched controls exhibited implications for 
treatment response with methylphenidate [107]. Individuals with 
BED and have at least one version of dopamine transporter 
associated with 9-repeat allele experience greater appetite 
suppression relative to methylphenidate. The findings proposed that 
an unidentified genetic variant overrepresented in BED intervene 
dopamine transporter to suppress appetite responding to stimulant 
administration. 
A double-blind, drug-placebo, cross-over study examined gender 
differences in methylphenidate response to a single dose and 
evaluated whether BED status moderated the predicted differences. 
The study was conducted on overweight or obese patients with BED 
(n =90) and without BED (n =108). After oral administration of the 
drug/placebo, ratings of appetite and food cravings have been 
evaluated through a laboratory-based snack-food challenge as well 
as emotional/mood ratings were evaluated every 15 min. Women 
demonstrated significantly greater sustained responses than their 
male. Among the women, a significantly greater reduction from the 
placebo was observed in measures of appetite and food cravings. 
While the two conditions showed similar outcomes in any of the 
food-related variables among men [108]. In a 12-week randomized 
study, the effectiveness of methylphenidate versus CBT has recently 
been evaluated in BED treatment. The trial conducted on 49 BE 
women randomly to receive methylphenidate (n=22) or CBT (n=27). 
Administration of methylphenidate and CBT was accompanied by a 
significant improvement in binge episodes features and quality of 
life. However, methylphenidate had a greater impact on BMI 
reduction compared to CBT [109]. 
Anti-addiction medications 
The progress into the biological basis of the addictive disorders 
showed a high comorbidity rates between addiction and eating 
disorders, such that addicted to highly palatable food contributes to 
develop and maintain obesity [110]. This is attributed to have 
comparable diagnosis, characterized by cravings, and feeling of loss 
of control over addicted substances or food [111]. These findings 
promote an assumption that addictive disorders and binge eating 
may share common pathophysiological and psychological cores. For 
instance, abused drugs and highly palatable food induce the same 
brain reward circuits and that anti-addiction medications may 
modulate various neurotransmitter systems such as GABA, 
dopamine, glutamate, and cannabinoid that comprise this circuitry 
[112]. These findings above urge the assessment of drugs used for 
addiction as a potential therapy for BED. 
Baclofen  
Baclofen is a GABA agonist and helps to treat alcoholism and 
addictive substances with cocaine, methamphetamine, nicotine, and 
heroin [113]. An open-label pilot study was conducted on 4 BE 
females and 3 bulimic females receiving baclofen (60 mg/day) for 10 
w [113]. Baclofen treatment was accompanied by reducing the 
binge-eating frequency in all participants without serious adverse 
effects. Five patients (including 3 BED) experienced a significant 
reduction in the frequency of weekly binge episodes. Also, there 
were no binge eating episodes in three patients (including 2 BED). 
These promising results were confirmed in a randomized, double-
blind, controlled, crossover trial involving 12 BE participants. The 
results were obtained during a run-in period, placebo phase (48 d), 
and baclofen phase (up to 60 mg/day for 48 d). Compared to 
placebo, the baclofen phase revealed a significant decrease in binge 
eating frequency with improving depressive symptoms. Baclofen 
and placebo phases have similar significant reductions in food 
cravings and binge severity (BES score) [114]. A case series (n =5) 
stated the efficacy of high-dose baclofen in BED treatment [115]. 
However, the evidence of these studies is restricted due to small 
sample size of participants. 
Opioid antagonists  
The opioid system was closely associated with the rewarding 
influence of consuming palatable food. Administration of opioid 
receptor agonist increases food intake, while opioid receptor 
antagonist decreases it [116]. Clinical studies suggest that the 
increased pain threshold in eating disorders patients shows 
abnormalities in the opiate system that involved in eating behavior, 
reward, and addiction [117].  
Several studies showed the efficacy of the opiate antagonist naltrexone 
in improving binge features and hunger attacks in obese people due to 
its role in the dopamine reward circuitry [118, 119]. In an open-label 
trial, binge eating and purging behaviors was significantly reduced in 
bulimic individuals receiving naltrexone (200 to 300 mg) and this 
outcome was established at 3 to 5 mo follow-up [120]. The same team 
research conducted another open-label trial for 6 w on 16 individuals 
with bulimia nervosa to evaluate naltrexone in either standard (50-
100 mg/day) or higher (200-300 mg/day) doses [121]. There was only 
a significant decrease in of binge-eating frequency related to the 
elevated doses of naltrexone. It is hypothesized that the difference in 
response to opioid receptors may be referred to the mechanism of 
action. Naltrexone is a weak κ-opioid receptor antagonist associated 
with eating behaviors; therefore, only the high doses could achieve an 
adequate receptor blockade.  
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Several studies widely investigated the use of naltrexone as part of 
combination therapies in recent years. One such combination, 
naltrexone in combination with antidepressant bupropion extended-
release, is allowed for weight control as an adjuvant to diet and 
physical activity and they may be more effective in the treatment of 
BED comorbid with obesity [122]. A randomized, double-blind, 
controlled, phase 3 trial of 1742 participants showed that sustained-
release tablets of naltrexone/bupropion combination were 
significantly superior to placebo in weight loss (p<0.0001) [58]. In 
another 24-week open-label study, 25 females with moderate to 
severe BED received the combination of naltrexone (32 mg/day) and 
bupropion (360 mg/day) tablets [59]. A significant improvement in 
binge severity (BES score) was reported in 83% of patients at 24-
week accompanied by a reduction in symptoms of depression and 
weight control. Furthermore, a randomized, double-blind, controlled 
study of 41 overweight binge eaters and 28 normal-weight bulimics 
investigated the outcome of naltrexone and imipramine in eating 
disorders. Patients received daily doses of naltrexone (100-150 
mg/day) and imipramine (50-150 mg/day) for 8 w. Both 
medications significantly decreased the duration and frequency of 
binge episodes in the overweight binge eaters (P =0.02) [123]. Of 
interest, research progress has presented that targeting reward 
systems can also select the suppression of certain types of food 
intakes that are very reinforcing, foods such as fatty or sugary food 
containing a huge number of calories but with low nutritional value 
[124]. Based on this hypothesis, baclofen and naltrexone efficacy 
were assessed in rats with BED, alone or in combination. 
Combination treatment was superior to either medication alone in 
effectively reducing excessive consumption of fatty or sugary foods 
related to binge eating [125, 126]. Furthermore, two case reports 
outlined the effective combination of fluoxetine with naltrexone 
(100 mg/day). One case showed decreases in binge symptoms and 
weight in an elderly female with a history of BED and severe 
depression upon adding naltrexone to fluoxetine (60 mg/day), diet, 
and CBT [127]. The other case was a patient with depression and 
posttraumatic stress disorder whose both BED and sexual 
dysfunction remitted with naltrexone [128]. Naloxone is another 
opioid antagonist that has revealed some favorable effects in BED 
when administered through intranasal route [129]. Additionally, 
nalmefene is a new compound combining μ and δ receptor 
antagonist and κ receptor partial agonist. The direct contribution of 
the opioid system in alcohol reward process and the indirect 
modulation of dopaminergic transmission in the mesolimbic areas 
are considered the main mechanism of nalmefene action to reduce 
alcohol intake [130]. In animal models, nalmefene resulted in being 
more effective than naltrexone, another opioid modulator shown to 
be effective in BED [131]. A case report also presented the potential 
use of nalmefene in BED therapy and other food craving disorders 
[132].  
ALKS-33 
ALKS-33 is an alcohol dependence modulator that selectively binds 
to µ, κ, and δ-opioid receptors [133]. In contrast to naltrexone, it is 
not subjected to first-pass metabolism increasing its oral 
bioavailability. A 6-week randomized, double-blind, controlled trial 
assessed the efficacy of ALKS-33 in 62 obese patients with BED 
[134]. Although ALKS-33 significantly decreased the frequency of 
weekly binge episodes and weight, the decrease was not significant 
relative to placebo. 
Acamprosate  
Acamprosate is an N-methyl-D-aspartate glutamate receptor 
antagonist allowed for abstinence maintenance in alcohol 
dependence [135, 136]. Along with BED was associated with 
substance use disorders, various studies proposed that reduced 
glutamate activity may reduce food intake in binge eating [112]. In a 
10-week, randomized, double-blind trial, 40 participants received 
the placebo or acamprosate (2,997 mg daily) [137]. Although 
acamprosate did not significantly reduce the frequency of binge 
episodes or any other findings in the longitudinal analysis, a 
significant improvement was observed in frequency of binge-eating 
days and psychopathological of obsessive-compulsiveness outcomes, 
and quality of life in the secondary endpoint analysis.  
Other drugs 
Memantine  
Memantine is a nootropic glutamate-modulating drug that in two 
small open-label trials appeared to decrease the frequency of binge 
episodes in BED. In the first, five obese women with BED were 
treated in the morning with memantine (10 mg) and late evening 
with memantine (10–20 mg) with weight loss (1.2 kg/week) [138]. 
In the second, 16 participants received for 12 w memantine (5 to 20 
mg/day) [139]. Memantine significantly decreased binge eating 
frequency with improving the severity of illness, although it did not 
significantly reduce body weight and BMI. 
Sodium oxybate  
Sodium oxybate, γ-hydroxybutyrate sodium salt, is allowed in 
patients with narcolepsy for the therapy of excessive daytime 
sleepiness and cataplexy [140]. The efficacy of sodium oxybate in 
BED treatment may be attributed to several rationals. γ–
hydroxybutyrate. The drug modulates a number of 
neurotransmitters such as GABA, dopamine, serotonin, opioids, and 
glutamate involved in feeding behaviors [141]. Patients with 
narcolepsy also experienced weight loss after receiving sodium 
oxybate treatment. Moreover, γ-hydroxybutyrate was associated 
with suppression of alcohol cravings and thus decreasing alcohol 
consumption in patients with alcohol overuse disorders. The ability 
to manage drug cravings and abuse may also be linked to suppress 
aspects of excess feeding behaviors food cravings, in view of the 
common association between addictive disorders and BED. There 
was only an open-label trial of 12 participants with BED evaluating 
the efficiency of sodium oxybate for 16 w in BED treatment [142]. 
Ten participants finished at least one post-baseline assessment, and 
five finished the trial due to the absence of efficacy, side effects, or 
other reasons for losing follow-up. Sodium oxybate significantly 
reduced the frequency of binge episodes, binge days, and body 
weight as well as improving symptoms of obsessive compulsion. 
Chromium picolinate 
Chromium is a vital mineral improving the regulation of mood, appetite, 
and glucose. Chromium directly enhances insulin [143] and serotonin 
functioning [144] and may also be downstream effectors of signaling 
pathways modulated by dopamine. These neurotransmitters have 
similar pathway of protein kinase that related to food consumption and 
homeostatic control of energy [145], rendering it a possible candidate for 
treating BED with comorbid depressive symptoms. In a 6-month, 
randomized, double-blind pilot trial, 24 overweight adults with BED 
received one of three treatments: placebo (n=7) or chromium at higher 
doses (1000 mcg daily, n=8) or chromium at moderate doses (600 mcg 
daily, n=9) [146]. No confirmed results about reductions in the frequency 
of binge episodes, body weight, and depressive features in two 
chromium groups relative to placebo group. Also, both chromium groups 
experienced a decrease in fasting glucose, with greater efficiency 
observed with chromium at higher dose. 
CONCLUSION 
BED is an area of profound health and societal issue. Current 
research concerning pharmacological therapies for BED remains in 
its early stages. Throughout the years, numerous guidelines and 
approaches have been planned for BED treatment. Unfortunately, 
several of the current BED pharmacotherapy research are 
overwhelmed by constraints for instance, inadequate sampling size, 
elevated placebo responses, elevated dropout rates, and uncertain 
correlation of results with clinical circumstances. There were not 
randomized controlled follow-up studies in a group of participants 
with binge-eating remission. Moreover, no pharmacotherapy studies 
have yet been released in children, teenagers, or elderly patients 
with BED. Lisdexamfetamine is the first medication officially allowed 
by the FDA to treat BED that significantly decreases binge eating 
frequency. Current data exhibit that some medications from 
different pharmacological classes may be useful in improving the 
primary BED-related findings. Medications that proposed for 
concurrent psychiatric instances (including weight, anxiety, or 
depression) with relative effectiveness and good tolerability for BED 
treatment may be upgraded to first-line therapy. 
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From findings, pharmacotherapy has a great help in improvement of 
BED outcomes; however, till now, no drug is recommended for all 
patients. Subsequently, a general therapy hierarchy for BED cannot 
be established as the drug of choice depends deeply on the 
particular features of each patient regarding both efficacy and 
tolerability. Further pharmacotherapy research for the medications 
is greatly needed at a large clinical scale for additional systematic 
assessment. Moreover, it is desirable to investigate new drugs and 
drug combinations from various classes with the intervention of 
nonpharmacological therapy to get maximum benefits and/or to 
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